---
title: "暉致第二季度財報即將發佈：有哪些值得期待的內容"
description: "製藥公司暉致（NASDAQ:VTRS）將在週四公佈其第二季度財報，華爾街預計每股收益（EPS）為 0.56 美元，下降 19%，收入為 34.6 億美元，下降 9%。暉致在過去一年中 75% 的時間裏超出了每股收益和收入的預期。該股今年已下跌近 29%，主要歸因於產品線的挫折和研發失敗，導致分析師將其評級為持有。最近的修訂顯示每股收益和收入預期的變化喜憂參半"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/251864780.md"
published_at: "2025-08-06T14:32:46.000Z"
---

# 暉致第二季度財報即將發佈：有哪些值得期待的內容

> 製藥公司暉致（NASDAQ:VTRS）將在週四公佈其第二季度財報，華爾街預計每股收益（EPS）為 0.56 美元，下降 19%，收入為 34.6 億美元，下降 9%。暉致在過去一年中 75% 的時間裏超出了每股收益和收入的預期。該股今年已下跌近 29%，主要歸因於產品線的挫折和研發失敗，導致分析師將其評級為持有。最近的修訂顯示每股收益和收入預期的變化喜憂參半

Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post EPS of $0.56, implying a fall of nearly 19% while revenue is expected to decline about 9% to $3.46 billion during the quarter. Over the last one year, V...

### Related Stocks

- [VTRS.US - 暉致](https://longbridge.com/zh-HK/quote/VTRS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| How Is The Market Feeling About Viatris Inc? | Viatris Inc's short interest has increased by 12.02%, with 26.26 million shares sold short, representing 2.61% of availa | [Link](https://longbridge.com/zh-HK/news/270733862.md) |
| Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer \| VTRS Stock News | Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer, a role aimed at enhancing the co | [Link](https://longbridge.com/zh-HK/news/271946525.md) |
| FDA Approves Viatris Generic Version of Sandostatin LAR Depot | The FDA has approved Viatris' generic version of Sandostatin LAR Depot. The FDA also accepted Viatris' New Drug Applicat | [Link](https://longbridge.com/zh-HK/news/270153300.md) |
| Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for | [Link](https://longbridge.com/zh-HK/news/268835258.md) |
| Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials | Viatris announced FDA approval for octreotide acetate, a generic version of Sandostatin LAR Depot, for treating acromega | [Link](https://longbridge.com/zh-HK/news/270166060.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
